Neurocrine Biosciences Forecasts Ingrezza (Valbenazine) Full Year 2024 Net Product Sales Guidance Of $2.1B-$2.2B
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has projected its Ingrezza (Valbenazine) net product sales for the full year 2024 to be between $2.1 billion and $2.2 billion.
February 07, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences forecasts Ingrezza sales for 2024 to reach $2.1B-$2.2B, indicating strong revenue growth.
The projected increase in Ingrezza sales for 2024 suggests a positive outlook for Neurocrine Biosciences' revenue growth. This forecast could lead to increased investor confidence in NBIX, potentially driving up the stock price in the short term. The specificity of the forecast and its focus on a key product underline its significance for the company's financial health.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100